Skip to content

Virtual Agent Feasibility in Oncology Patients (NTT Data)

A Randomized Pilot Study Comparing the Feasibility of Using a Virtual Agent vs. an Off-site Human Agent to Onboard Oncology Patients to a Remote Monitoring Device

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06682013
Enrollment
0
Registered
2024-11-12
Start date
2026-05-01
Completion date
2026-05-01
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The purpose of this study is to compare the use of a virtual agent vs. a human agent when onboarding oncology patients over the telephone to Remote Patient Monitoring (RPM) devices. RPM devices are instruments that a patient can use to measure their own weight and vital signs. Both the virtual and human agents will be available by telephone to instruct the patient on how to use the RPM devices to measure weight, blood pressure, heart rate, temperature, and oxygen saturation. Patients will be randomized to either the virtual or human agent, have assessments of their medical and oncological history, overall well-being, body measurements, and vital signs, and will complete questionnaires about their experience.

Interventions

DEVICEVirtual agent

The virtual agent is an interactive audio agent that is similar to voice agents that interact with callers in many industries today. They create a very human-like interaction in contrast to more traditional virtual call agents that can only respond to menu options (e.g. "choose "1" for appointments, choose "2" for questions about your bill", etc.). The virtual agent is engineered to accomplish the very specific task of onboarding the patient on use of the RPM devices. It is trained to understand normal human English speech, detects emotional tone and frustration of callers, and is trained to deescalate when appropriate.

OTHERHuman agent

The human agent will onboard the patient on use of the RPM devices.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information. 2. Age ≥18 3. Cancer (solid tumor) 4. Planning to return to Duke Cancer Center clinic for three days in a row * Patients whose treatment does not require that they return to clinic for three days in a row, but who are willing to voluntarily return to participate in this study are permitted to enroll. 5. Eastern Cooperative Oncology Group (ECOG) score of 0-2 6. Native fluency of spoken English as determined by the investigator * Non-native English speakers are permitted to enroll if they have achieved native fluency. 7. Vitals as collected by the clinic using Duke maintained equipment must be within the ranges specified by the remote patient monitoring devices. * Weight ≤ 180 kg * Systolic blood pressure ≤ 300 mmHg * Pulse rate of 40-200 bpm * SpO2 of 70-100% * Temperature 34.0-42.2°C 8. Arm circumference of 22-42 cm

Exclusion criteria

1. 1\. Vision, speech, auditory, physical, cognitive or other impairment that has the potential to interfere with the use of the remote patient monitoring device or agent, in the opinion of the investigator or study coordinator. 2. Has an implanted pacemaker, arterio-venus (A-V) shunt, a history of mastectomy or lymph node clearance, history of severe blood flow problems or blood disorders, or a history of severe circulatory deficit in the arm. 3. Is pregnant

Design outcomes

Primary

MeasureTime frameDescription
Usability of virtual agent vs. human agent for onboarding patients to RPM devices as assessed by the System Usability Scale (SUS)Day 1, Day 2, Day 3The SUS is a questionnaire that assesses perceived usability. It includes 10 five-point items with alternating positive and negative tone. The final score is a number 0-100 with a higher score indicating better usability.

Secondary

MeasureTime frameDescription
Description of the patient experience when using a virtual agent in the context of teaching a patient as assessed by the patient experience survey.Day 3The patient experience survey includes 3 open-ended questions about experience with the training process, input on using monitoring devices at home, and any other important information for the researchers to know. Descriptive analysis will be conducted within each arm.
Identification of opportunities to improve the use of a virtual agent in the context of teaching a patient as assessed by the patient experience survey.Day 3The patient experience survey includes 3 open-ended questions about experience with the training process, input on using monitoring devices at home, and any other important information for the researchers to know. Descriptive analysis will be conducted within each arm.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLaura Alder, MD

Duke University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026